시장보고서
상품코드
1301102

임상시험 용품 시장 규모, 점유율 및 동향 분석 보고서 : 임상 단계별, 제품 및 서비스별, 최종 용도별, 치료 용도별, 지역별, 부문별 예측(2023-2030년)

Clinical Trial Supplies Market Size, Share & Trends Analysis Report By Clinical Phase (Phase I, Phase II, Phase III), By Product & Services, By End-Use, By Therapeutic Use, By Region, And Segment Forecasts, 2023 - 2030

발행일: | 리서치사: Grand View Research | 페이지 정보: 영문 123 Pages | 배송안내 : 2-10일 (영업일 기준)


※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

임상시험 용품 시장의 성장과 동향

Grand View Research, Inc.의 최신 보고서에 따르면, 세계 임상시험 용품 시장 규모는 2023년부터 2030년까지 CAGR 6.5%로 확대되어 2030년에는 34억 달러에 달할 것으로 예상됩니다.

임상시험의 증가와 시험 수행의 복잡성은 시장 성장을 촉진하는 주요 요인 중 하나입니다.

전 세계적으로 만성질환의 유병률 증가와 급속한 고령화가 생물학적 제제 연구개발의 성장을 촉진할 것으로 예상되며, 이는 효율적인 임상용품에 대한 수요를 더욱 촉진하여 임상시험용품 산업의 성장에 기여할 것으로 예상됩니다. 또한, 희귀질환 치료제 수요 증가와 희귀질환 연구개발에 대한 높은 투자도 생물학적 제제 개발에 기여할 것으로 예상됩니다. 이러한 요인으로 인해 이 부문은 예측 기간 동안 큰 성장을 이룰 가능성이 높습니다.

예를 들어, 노바티스는 2022년 연구개발에 약 100억 달러를 투자했습니다. 또한 유럽연합(EU), 일본, 중국, 미국에서 23건의 신약 및 희귀질환에 대한 승인을 받았습니다. 또한 인도에서 44개의 임상 3상 프로그램을 진행 중이며, 비정형 용혈성 요독 증후군(aHUS), 면역성 혈소판 감소성 자반병(ITP), 척수성 근위축증(SMA), 루푸스 신염 등 희귀질환에 대한 17개의 임상 프로그램을 진행 중입니다.

DTP(Direct-to-Patient)는 임상시험용 의약품 유통의 미래 유통 모델로 기대되는 분야로, 환자에게 직접 약물을 전달하여 환자 중심의 임상시험을 진행하는 새로운 모델 중 하나입니다. 이는 임상시험 기관을 방문하는 횟수를 줄여 참가자의 부담을 줄여주며, COVID-19 사태로 인해 최소한의 혼란으로 임상시험 연구를 지속하기 위해 이러한 모델의 채택이 증가하고 있습니다. 또한, 환자 유지와 전 세계의 다양한 환자 풀은 이 모델의 높은 채택률에 기인하는 중요한 이유 중 하나입니다.

임상시험 용품 시장 보고서 하이라이트

  • 임상 단계에 따라 2022년 매출 점유율은 임상 3상 시험이 52.7%를 차지하며 시장을 독점할 것으로 예상됩니다. 현재 임상 3상 시험 중인 분자가 많다는 점이 매출 감소의 주요 원인으로 작용하고 있습니다.
  • 서비스 중 보관 및 유통 분야는 예측 기간 동안 CAGR 6.8%로 가장 빠르게 성장할 것으로 예상됩니다. 세계 바이오의약품 파이프라인의 증가와 온도에 민감한 의약품의 증가로 인해 임상시험용 의약품의 물류에 대한 복잡성이 증가할 것으로 예상됩니다.
  • 생물학적 제제는 나노입자 기반 약물전달 시스템 개발 등 유전학 및 생명공학 분야의 연구 증가로 인해 예측 기간 동안 CAGR 6.7%로 가장 빠른 성장을 보일 것으로 예상됩니다.
  • 치료용으로는 종양학이 2022년 38.8%의 매출 점유율로 시장을 장악하고 있으며, United Press International에 따르면 미국 병원에서는 부적절한 투여로 인해 수십억 개의 항암제 바이알이 폐기되고 있어 적절한 공급 관리의 필요성이 지적되고 있습니다.

목차

제1장 조사 방법과 범위

  • 시장 세분화와 범위
  • 지역 범위
  • 추정·예측 타임라인
  • 목적
  • 조사 방법
  • 정보 조달
  • 정보 또는 데이터 분석
  • 시장 형성과 검증
  • 모델 상세
  • 2차 정보 리스트
  • 약어 리스트

제2장 주요 요약

  • 시장 전망
  • 부문 전망
  • 경쟁 인사이트

제3장 임상시험 용품 시장 변수, 동향, 범위

  • 시장 계통 전망
    • 상부 시장 전망
    • 관련/보조적인 시장 전망
  • 시장 역학
    • 시장 성장 촉진요인 분석
    • 시장 성장 억제요인 분석
  • 임상시험 용품 시장 분석 툴
    • 업계 분석 - Porters 분석
    • PESTEL 분석
    • COVID-19 감염증의 영향 분석

제4장 임상시험 용품 시장 : 임상 단계 추정·동향 분석

  • 임상시험 용품 시장, 임상 단계별 : 부문 대시보드
  • 임상시험 용품 시장, 임상 단계별 : 변동 분석
    • 단계 I
    • 단계 II
    • 단계Ⅲ
    • 단계 IV
    • 기타

제5장 임상시험 용품 시장 : 제품과 서비스 추정·동향 분석

  • 임상시험 용품 시장, 제품 및 서비스별 : 부문 대시보드
  • 임상시험 용품 시장, 제품 및 서비스별 : 변동 분석
    • 제조업
    • 보관과 배포
    • 공급망 관리

제6장 임상시험 용품 시장 : 치료 분야 추정·동향 분석

  • 임상시험 용품 시장, 치료 분야별 : 부문 대시보드
  • 임상시험 용품 시장, 치료 분야별 : 변동 분석
    • 종양학
    • 중추신경계
    • 심혈관
    • 감염증
    • 대사장애
    • 기타

제7장 임상시험 용품 시장 : 최종 사용 추정·동향 분석

  • 임상시험 용품 시장, 최종 사용별 : 부문 대시보드
  • 임상시험 용품 시장, 최종 사용별 : 변동 분석
    • 의약품
    • 생물제제
    • 의료기기
    • 기타

제8장 임상시험 용품 시장 : 지역 추정·동향 분석

  • 지역 시장 점유율 분석, 2022년 및 2030년
  • 지역 시장 대시보드
  • 세계의 지역 시장 현황
  • 북미
    • 시장 추정과 예측, 2018-2030년(매출)
    • 미국
    • 캐나다
  • 유럽
    • 영국
    • 독일
    • 프랑스
    • 이탈리아
    • 스페인
    • 덴마크
    • 스웨덴
    • 노르웨이
  • 아시아태평양
    • 일본
    • 인도
    • 중국
    • 한국
    • 호주
    • 태국
  • 라틴아메리카
    • 브라질
    • 멕시코
    • 아르헨티나
  • MEA
    • 남아프리카공화국
    • 사우디아라비아
    • 아랍에미리트
    • 쿠웨이트

제9장 경쟁 상황

  • 시장 진출 기업 분류
    • 이노베이터
    • 시장 리더
    • 신흥 기업
    • 기업의 시장 점유율 분석, 2022년
  • 기업 개요
    • Almac Group
    • Biocair
    • Catalent, Inc.
    • KLIFO
    • Movianto
    • PCI Pharma Services
    • Sharp Services, LLC
    • Thermo Fisher Scientific, Inc.
    • Marken
    • Paraxel International Corporation
ksm 23.07.21

Clinical Trial Supplies Market Growth & Trends

The global clinical trial supplies market size is expected to reach USD 3.4 billion by 2030, expanding at 6.5% CAGR from 2023 to 2030, according to a new report by Grand View Research, Inc. Increasing volume of clinical trial studies coupled with the growing complexity in conduction of these trials are some of the major factors driving the market growth.

Globally, an increase in the prevalence of chronic diseases and the rapidly aging population are expected to drive the growth of R&D of biologics, which is expected to further propel the demand for efficient clinical supplies and contribute to the growth of the clinical trial supplies industry. Furthermore, an increase in the demand for orphan drugs and high investment in the R&D of rare diseases are also expected to contribute toward the development of biologic drugs. Thus, owing to these factors, this segment is likely to witness significant growth during the forecast period.

For instance, in 2022, Novartis invested around USD 10 billion in research and development. It also secured 23 approvals in the European Union, Japan, China, and the U.S. for new drugs and rare diseases. The company is also conducting 44 ongoing phase III programs in India with 17 clinical programs running in rare diseases such as atypical hemolytic uremic syndrome (aHUS), Immune thrombocytopenic purpura (ITP), spinal muscular atrophy (SMA), and Lupus Nephritis.

Direct-to-Patients (DTP) is an upcoming segment in the distribution of clinical trial supplies, which is expected to be the future model of distribution. DTP is one of the emerging models that involves delivering drugs to patients directly to create patient-centric trials. This would facilitate fewer visits to the site and reduce the burden on participants. The COVID-19 outbreak has led to the increased adoption of such a model, to continue clinical trial studies with minimum disruption. In addition, patient retention and a diverse pool of patients worldwide are some of the notable reasons that can be attributed to the high adoption of this model.

Clinical Trial Supplies Market Report Highlights

  • Based on the clinical phase, the market is anticipated to be dominated by the Phase III trial segment with a 52.7% revenue share in 2022. The presence of a large number of molecules currently under Phase III makes it the primary factor responsible for this deduction
  • Among services, the storage, and distribution segment is anticipated to witness the fastest growth at a CAGR of 6.8% during the forecast period. The rise in global biologics pipeline and temperature-sensitive drugs is expected to increase the complexities related to the logistics of clinical trial supplies
  • Biologics are expected to witness the fastest growth at 6.7% CAGR during the forecast period owing to the increasing research in the field of genetics and biotechnology such as the development of nanoparticle-based drug delivery systems
  • In terms of therapeutic use, oncology dominated the market with a revenue share of 38.8% in 2022. According to the United Press International, hospitals in the U.S. are disposing of billions of cancer drug vials due to improper dosage, thereby indicating the need for appropriate supply management

Table of Contents

Chapter 1. Research Methodology And Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Segment Definitions
    • 1.1.2. Clinical Phase
    • 1.1.3. Product & Services
    • 1.1.4. End Use
    • 1.1.5. Therapeutic Area
  • 1.2. Regional Scope
  • 1.3. Estimates And Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information Or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
    • 1.9.2. Parent Market Analysis
  • 1.10. List Of Secondary Sources
  • 1.11. List Of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Clinical Trial Supplies Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Expansion of clinical trials sites
      • 3.2.1.2. Growing R&D in biologics and biosimilar
      • 3.2.1.3. Advancements in supply chain technology
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Presence of stringent regulatory policies
      • 3.2.2.2. High Possibility of Counterfeiting Drugs
  • 3.3. Clinical Trial Supplies Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Clinical Trial Supplies Market: Clinical Phase Estimates & Trend Analysis

  • 4.1. Clinical Trial Supplies Market, By Clinical Phase: Segment Dashboard
  • 4.2. Clinical Trial Supplies Market, By Clinical Phase: Movement Analysis
  • 4.3. Clinical Trial Supplies Market Estimates & Forecasts, By Clinical Phase, 2018 - 2030
    • 4.3.1. Phase I
      • 4.3.1.1. Phase I Clinical Trial Supplies Market, 2018 to 2030 (USD Billion)
    • 4.3.2. Phase II
      • 4.3.2.1. Phase II Clinical Trial Supplies Market, 2018 to 2030 (USD Billion)
    • 4.3.3. Phase III
      • 4.3.3.1. Phase III Clinical Trial Supplies Market, 2018 to 2030 (USD Billion)
    • 4.3.4. Phase IV
      • 4.3.4.1. Phase IV Clinical Trial Supplies Market, 2018 to 2030 (USD Billion)
    • 4.3.5. Others
      • 4.3.5.1. Others market, 2018 to 2030 (USD Billion)

Chapter 5. Clinical Trial Supplies Market: Product & Service Estimates & Trend Analysis

  • 5.1. Clinical Trial Supplies Market, By Product & Service: Segment Dashboard
  • 5.2. Clinical Trial Supplies Market, By Product & Service: Movement Analysis
  • 5.3. Clinical Trial Supplies Market Estimates & Forecasts, By Product & Service, 2018 - 2030
    • 5.3.1. Manufacturing
      • 5.3.1.1. Manufacturing Clinical Trial Supplies Market, 2018 to 2030 (USD Billion)
    • 5.3.2. Storage & Distribution
      • 5.3.2.1. Storage & Distribution Clinical Trial Supplies Market, 2018 to 2030 (USD Billion)
    • 5.3.3. Supply Chain Management
      • 5.3.3.1. Supply Chain Management Clinical Trial Supplies Market, 2018 to 2030 (USD Billion)

Chapter 6. Clinical Trial Supplies Market: Therapeutic Area Estimates & Trend Analysis

  • 6.1. Clinical Trial Supplies Market, By Therapeutic Area: Segment Dashboard
  • 6.2. Clinical Trial Supplies Market, By Therapeutic Area: Movement Analysis
  • 6.3. Clinical Trial Supplies Market Estimates & Forecasts, By Therapeutic Area, 2018 - 2030
    • 6.3.1. Oncology
      • 6.3.1.1. Oncology clinical trial supplies market 2018 to 2030 (USD Billion)
    • 6.3.2. CNS
      • 6.3.2.1. CNS clinical trial supplies market 2018 to 2030 (USD Billion)
    • 6.3.3. Cardiovascular
      • 6.3.3.1. Cardiovascular clinical trial supplies market 2018 to 2030 (USD Billion)
    • 6.3.4. Infectious disease
      • 6.3.4.1. Infectious disease clinical trial supplies market 2018 to 2030 (USD Billion)
    • 6.3.5. Metabolic disorders
      • 6.3.5.1. Metabolic Disorders Clinical Trial Supplies Market, 2018 to 2030 (USD Billion)
    • 6.3.6. Others
      • 6.3.6.1. Others clinical trial supplies market 2018 to 2030 (USD Billion)

Chapter 7. Clinical Trial Supplies Market: End-use Estimates & Trend Analysis

  • 7.1. Clinical Trial Supplies Market, By End-use: Segment Dashboard
  • 7.2. Clinical Trial Supplies Market, By End-use: Movement Analysis
  • 7.3. Clinical Trial Supplies Market Estimates & Forecasts, By End-use, 2018 - 2030
    • 7.3.1. Pharmaceutical
      • 7.3.1.1. Pharmaceutical Clinical trial supplies market 2018 to 2030 (USD Billion)
    • 7.3.2. Biologics
      • 7.3.2.1. Biologics clinical trial supplies market 2018 to 2030 (USD Billion)
    • 7.3.3. Medical Devices
      • 7.3.3.1. Medical devices clinical trial supplies market 2018 to 2030 (USD Billion)
    • 7.3.4. Others
      • 7.3.4.1. Others clinical trial supplies market 2018 to 2030 (USD Billion)

Chapter 8. Clinical Trial Supplies Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2022 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Global Regional Market Snapshot
  • 8.4. North America
    • 8.4.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Billion)
    • 8.4.2. U.S.
      • 8.4.2.1. Key country dynamics
      • 8.4.2.2. Competitive scenario
      • 8.4.2.3. Regulatory framework
      • 8.4.2.4. U.S. market estimates and forecasts, 2018 - 2030
    • 8.4.3. Canada
      • 8.4.3.1. Key country dynamics
      • 8.4.3.2. Competitive scenario
      • 8.4.3.3. Regulatory framework
      • 8.4.3.4. Canada market estimates and forecasts, 2018 - 2030
  • 8.5. Europe
    • 8.5.1. UK
      • 8.5.1.1. Key country dynamics
      • 8.5.1.2. Competitive scenario
      • 8.5.1.3. Regulatory framework
      • 8.5.1.4. UK market estimates and forecasts, 2018 - 2030
    • 8.5.2. Germany
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Competitive scenario
      • 8.5.2.3. Regulatory framework
      • 8.5.2.4. Germany market estimates and forecasts, 2018 - 2030
    • 8.5.3. France
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Competitive scenario
      • 8.5.3.3. Regulatory framework
      • 8.5.3.4. France market estimates and forecasts, 2018 - 2030
    • 8.5.4. Italy
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Competitive scenario
      • 8.5.4.3. Regulatory framework
      • 8.5.4.4. Italy market estimates and forecasts, 2018 - 2030
    • 8.5.5. Spain
      • 8.5.5.1. Key country dynamics
      • 8.5.5.2. Competitive scenario
      • 8.5.5.3. Regulatory framework
      • 8.5.5.4. Spain market estimates and forecasts, 2018 - 2030
    • 8.5.6. Denmark
      • 8.5.6.1. Key country dynamics
      • 8.5.6.2. Competitive scenario
      • 8.5.6.3. Regulatory framework
      • 8.5.6.4. Denmark market estimates and forecasts, 2018 - 2030
    • 8.5.7. Sweden
      • 8.5.7.1. Key country dynamics
      • 8.5.7.2. Competitive scenario
      • 8.5.7.3. Regulatory framework
      • 8.5.7.4. Sweden market estimates and forecasts, 2018 - 2030
    • 8.5.8. Norway
      • 8.5.8.1. Key country dynamics
      • 8.5.8.2. Competitive scenario
      • 8.5.8.3. Regulatory framework
      • 8.5.8.4. Norway market estimates and forecasts, 2018 - 2030
  • 8.6. Asia Pacific
    • 8.6.1. Japan
      • 8.6.1.1. Key country dynamics
      • 8.6.1.2. Competitive scenario
      • 8.6.1.3. Regulatory framework
      • 8.6.1.4. Japan market estimates and forecasts, 2018 - 2030
    • 8.6.2. India
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Competitive scenario
      • 8.6.2.3. Regulatory framework
      • 8.6.2.4. India market estimates and forecasts, 2018 - 2030
    • 8.6.3. China
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Competitive scenario
      • 8.6.3.3. Regulatory framework
      • 8.6.3.4. China market estimates and forecasts, 2018 - 2030
    • 8.6.4. South Korea
      • 8.6.4.1. Key country dynamics
      • 8.6.4.2. Competitive scenario
      • 8.6.4.3. Regulatory framework
      • 8.6.4.4. South Korea market estimates and forecasts, 2018 - 2030
    • 8.6.5. Australia
      • 8.6.5.1. Key country dynamics
      • 8.6.5.2. Competitive scenario
      • 8.6.5.3. Regulatory framework
      • 8.6.5.4. Australia market estimates and forecasts, 2018 - 2030
    • 8.6.6. Thailand
      • 8.6.6.1. Key country dynamics
      • 8.6.6.2. Competitive scenario
      • 8.6.6.3. Regulatory framework
      • 8.6.6.4. Thailand market estimates and forecasts, 2018 - 2030
  • 8.7. Latin America
    • 8.7.1. Brazil
      • 8.7.1.1. Key country dynamics
      • 8.7.1.2. Competitive scenario
      • 8.7.1.3. Regulatory framework
      • 8.7.1.4. Brazil market estimates and forecasts, 2018 - 2030
    • 8.7.2. Mexico
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Competitive scenario
      • 8.7.2.3. Regulatory framework
      • 8.7.2.4. Mexico Market estimates and forecasts, 2018 - 2030
    • 8.7.3. Argentina
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Competitive scenario
      • 8.7.3.3. Regulatory framework
      • 8.7.3.4. Argentina market estimates and forecasts, 2018 - 2030
  • 8.8. MEA
    • 8.8.1. South Africa
      • 8.8.1.1. Key country dynamics
      • 8.8.1.2. Competitive scenario
      • 8.8.1.3. Regulatory framework
      • 8.8.1.4. South Africa market estimates and forecasts, 2018 - 2030
    • 8.8.2. Saudi Arabia
      • 8.8.2.1. Key country dynamics
      • 8.8.2.2. Competitive scenario
      • 8.8.2.3. Regulatory framework
      • 8.8.2.4. Saudi Arabia market estimates and forecasts, 2018 - 2030
    • 8.8.3. UAE
      • 8.8.3.1. Key country dynamics
      • 8.8.3.2. Competitive scenario
      • 8.8.3.3. Regulatory framework
      • 8.8.3.4. UAE market estimates and forecasts, 2018 - 2030
    • 8.8.4. Kuwait
      • 8.8.4.1. Key country dynamics
      • 8.8.4.2. Competitive scenario
      • 8.8.4.3. Regulatory framework
      • 8.8.4.4. Kuwait market estimates and forecasts, 2018 - 2030

Chapter 9. Competitive Landscape

  • 9.1. Market Participant Categorization
    • 9.1.1. Innovators
    • 9.1.2. Market Leaders
    • 9.1.3. Emerging Players
    • 9.1.4. Company Market Share Analysis, 2022
  • 9.2. Company Profiles
    • 9.2.1. Almac Group
      • 9.2.1.1. Company overview
      • 9.2.1.2. Financial performance
      • 9.2.1.3. Service benchmarking
      • 9.2.1.4. Strategic initiatives
    • 9.2.2. Biocair
      • 9.2.2.1. Company overview
      • 9.2.2.2. Financial performance
      • 9.2.2.3. Service benchmarking
      • 9.2.2.4. Strategic initiatives
    • 9.2.3. Catalent, Inc.
      • 9.2.3.1. Company overview
      • 9.2.3.2. Financial performance
      • 9.2.3.3. Service benchmarking
      • 9.2.3.4. Strategic initiatives
    • 9.2.4. KLIFO
      • 9.2.4.1. Company overview
      • 9.2.4.2. Financial performance
      • 9.2.4.3. Service benchmarking
      • 9.2.4.4. Strategic initiatives
    • 9.2.5. Movianto
      • 9.2.5.1. Company overview
      • 9.2.5.2. Financial performance
      • 9.2.5.3. Service benchmarking
      • 9.2.5.4. Strategic initiatives
    • 9.2.6. PCI Pharma Services
      • 9.2.6.1. Company overview
      • 9.2.6.2. Financial performance
      • 9.2.6.3. Service benchmarking
      • 9.2.6.4. Strategic initiatives
    • 9.2.7. Sharp Services, LLC
      • 9.2.7.1. Company overview
      • 9.2.7.2. Financial performance
      • 9.2.7.3. Service benchmarking
      • 9.2.7.4. Strategic initiatives
    • 9.2.8. Thermo Fisher Scientific, Inc.
      • 9.2.8.1. Company overview
      • 9.2.8.2. Financial performance
      • 9.2.8.3. Service benchmarking
      • 9.2.8.4. Strategic initiatives
    • 9.2.9. Marken
      • 9.2.9.1. Company overview
      • 9.2.9.2. Financial performance
      • 9.2.9.3. Service benchmarking
      • 9.2.9.4. Strategic initiatives
    • 9.2.10. Paraxel International Corporation
      • 9.2.10.1. Company overview
      • 9.2.10.2. Financial performance
      • 9.2.10.3. Service benchmarking
      • 9.2.10.4. Strategic initiatives
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제